TORONTO, Jan. 10, 2019 — Canada House Clinics Inc., a division of Canada House Wellness Group Inc.
(CSE:CHV) (“Canada House”) and HelloMD, a leading online cannabis telehealth company are pleased to
announce a new medical cannabis partnership that supports Canada House’s 2019 growth through
expanded access to practitioner-led advice.
Canada House Clinics will deploy HelloMD’s white-label telehealth platform to supplement its own
practitioner’s services and telemedicine capabilities. The turnkey and on-demand nature of the
HelloMD offering will allow Canada House Clinics to handle growth spikes when patient demands
exceed its own internal practitioner supply and also take advantage of HelloMD evening and weekend
“Canada House is committed to helping Canadians interested in improving their health with
cannabinoid therapy,” said Canada House CEO Chris Churchill-Smith. “This partnership with HelloMD
allows us to expand and better manage our practitioner support for our patients, while we continue
to work with the medical community, insurers, and governments to improve the medical cannabis
program for all Canadians.”
Canada House patients using this option are greeted by a co-branded landing page on the HelloMD
platform and by HelloMD’s patient support team prior to being connected with a licenced
practitioner. Qualifying patients are immediately returned to Canada House and its team of
educators to facilitate the patients’ cannabis purchasing decisions.
“Given Canada House’s reputation, especially its unique strengths in serving the nation’s military
veterans, we are honoured they have chosen HelloMD as an on-demand provider of online practitioner
consults,” said HelloMD’s SVP of Business Development, Larry Lisser. “We pride ourselves in
assisting our partners to streamline the experience they offer patients and in doing so, help them to cost-efficiently expand their operations.”
Canada House Wellness Group Inc.
Canada House is an experienced, integrated medical cannabis company providing patient-specific cannabinoid therapy products and services through its clinics and licensed producer. Canada House is the parent company of Canada House Clinics Inc., Knalysis Technologies and Abba Medix Corp. For more information, please visit www.canadahouse.ca or www.sedar.com.
HelloMD has facilitated more than 100,000 virtual consults between medical cannabis patients and
licensed practitioners. The company’s white-label solutions enable third parties to quickly deploy
a turnkey telehealth solution, complete with the technology, practitioners and support personnel
required to improve their own patient onboarding processes.
For further information about HelloMD:
For Media Inquiries:
Garrett Repski, Project Manager, Marigold Marketing & PR, 1-647-972-2466, firstname.lastname@example.org
Cautionary Statement Regarding Forward Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements.
Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.